Company intelligence / Profile preview
Medsintez
Novouralsk, Sverdlovsk Region, Russia
- Ownership
- Private
- Development stage
- Other
01
Overview
Medsintez has several commercialized products, including genetically engineered human insulin (Rosinsulin), veterinary insulin, recombinant follicle-stimulating hormone (Primapur), and the direct-acting antiviral Triazavirin, demonstrating bioequivalence to international analogs and broad market distribution in Russia[1][2][3][4][6][7].
- Therapeutic areas
- Infectious DiseasesEndocrinologyWomen's Health
- Modalities
- Recombinant proteinSmall moleculeBiologic
- Industry
- Biotech
02
Drug pipeline
3 assets2 more assets in the full pipeline.
Request access →03
Partnerships
BayerSTADAiVFarma
Beyond the preview
Go deeper on Medsintez.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Medsintez.